[CAS NO. 1215493-56-3] RG2833 (RGFP109)
Please click "REQUEST A QUOTE" button if you need other sizes or custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis, please:
PRODUCTS SPECIFICATIONS [1215493-56-3]
Store
Catalog
SLK-S7292
Brand
Selleck
CAS
1215493-56-3
DESCRIPTION [1215493-56-3]
Overview
| MDL | MFCD25976845 |
|---|---|
| Molecular Weight | 339.43 |
| Molecular Formula | C20H25N3O2 |
| SMILES | O=C(NCCCCCC(NC1=CC=CC=C1N)=O)C2=CC=C(C)C=C2 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9461 mL | 14.7306 mL | 29.4612 mL |
| 5 mM | 0.5892 mL | 2.9461 mL | 5.8922 mL |
| 10 mM | 0.2946 mL | 1.4731 mL | 2.9461 mL |
| 50 mM | 0.0589 mL | 0.2946 mL | 0.5892 mL |
Description
RG2833 (RGFP109) is a brain-penetrant inhibitor with of 60 nM and 50 nM for HDAC1 and HDAC3 in cell-free assays, respectively.
Features
Orally bioavailable, HDAC inhibitor that penetrates into brain tissue.
In vitro
RGFP109 dose-dependently upregulates frataxin mRNA and protein levels in cultures of unstimulated peripheral blood mononuclear cells (PBMC) obtained from FRDA patients.
In vivo
RG2833 (150 mg/kg) corrects frataxin deficiency and increases histone acetylation in the brain and heart of KIKI mice without acute toxicity signs. RGFP109 ameliorates the disease phenotype of a Friedreich ataxia mouse model. RGFP109 (30 mg/kg p.o.) also alleviates established l-DOPA-induced dyskinesia.
References
Powered by Arctom Copyright © 2026 Arctom. All rights
reserved.